Business Wire

Verimatrix Brings Effortless Application Security to the Masses, Launches New ProtectMyApp Service for Developers

Share

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190708005254/en/

Verimatrix Introduces ProtectMyApp Service - Is Your App Secure? (Photo: Business Wire)

Verimatrix Introduces ProtectMyApp Service - Is Your App Secure? (Photo: Business Wire)

Verimatrix (Paris:VMX), a global provider of security and analytics solutions that protect devices, services and applications, today announced the launch of ProtectMyApp, a groundbreaking new service designed to bring cost-effective mobile application security to developers — providing an unmatched level of simplicity and speed to the protection phase of app development.

With rampant reverse engineering and tampering activities that can lead to potentially devastating vulnerabilities, financial losses and data theft, today’s mobile application developers seek an answer to ever-mounting cyber threats. Developers can now sign up at www.ProtectMyApp.com and easily upload their final, compiled applications and receive the protected application back in just minutes without the need for security expertise.

“This is where application security is moving. It is a first-of-its-kind cloud service that truly changes how developers of all sizes can approach protection,” said Asaf Ashkenazi, chief strategy officer at Verimatrix, previously known as Inside Secure. “Facing time, budget and talent hurdles, ProtectMyApp handles the heavy lifting for developers that face the daunting threats we see every day in the press. Now, they simply upload their application, and receive it back protected. What previously required extensive expertise, time and effort, is now efficiently offered by an intelligent automated service that optimizes protection without compromising performance or user experience.”

Sign Up to Protect against Today’s Most Advanced Threats
Once subscribed to the service at www.ProtectMyApp.com, for a limited time, users are offered one free protection of an application on iOS and Android. Protection takes place on demand at any time, for any version, including updates to the application. The cloud-based service is the answer to the industry’s most acute problems, including:

  • Compromised Devices – Jailbroken/rooted devices, hooking frameworks, debuggers and emulators pose huge risks because they break down defenses that operating systems provide to the apps running on the device.
  • Reverse Engineering – Attackers analyze apps to learn secrets and gain knowledge needed to launch an attack on an app.
  • Repackaging – Though it does not get the headlines it deserves, malware is often delivered by repackaging a legitimate application, which involves pulling apart an original app, adding code and republishing it to look and act genuine when it is really a trojan horse for attackers.
  • Rogue Access – Most apps connect to a cloud service. Since an app is considered relatively trusted by its service, it directly accesses the service, bypassing the service’s firewalls and other network protection mechanisms. A compromised app can be used to bypass the service’s network protections, discover vulnerabilities in the service’s interface, and compromise the service.

Works on All Types of Applications
ProtectMyApp is packed with security techniques that protect against the above-mentioned threats, which can damage reputation, adversely affect revenue and compromise sensitive data. Whether an application is designed to be an interface, such as an airline or vehicle app, or an application serves as the actual business interface, such as banking, gaming or medical services, ProtectMyApp is a simple, innovative choice for developers that need reassurance and peace of mind.

Its unique features allow developers to:

  • Protect – Uses automated protection that does not require manually setting protection points. Intelligent optimization provides the best balance between security and performance while unparalleled self-protection capabilities are independent of device/operating system security level.
  • Detect – Combines client security with powerful cloud intelligence to detect potential disasters in advance. Application protection data is sent to ProtectMyApp, which uses powerful analytics technology to provide security alerts to developers.
  • Act – Arms developers with the ability to terminate application execution when an imminent threat is detected. Developers can easily eliminate exploits before damage is done, deny access to service for applications running on emulators or debuggers, and block cloned or repackaged applicationss from access to the service.

“ProtectMyApp is a powerful service that protects applicationss in minutes — all through an affordable monthly service subscription that can make the difference between a smartphone app vulnerability that is exploited and a vulnerability that was never discovered,” Ashkenazi continued. “This type of service is a true industry first, enabling application developers to automate protection using a proven technological leader without breaking the bank.”

About Verimatrix
Verimatrix (Euronext Paris – VMX) is a global provider of security and analytics solutions that protect devices, services and applications across multiple markets. Many of the world’s largest service providers and leading innovators trust Verimatrix to protect systems that people depend on every day for mobile apps, entertainment, banking, healthcare, communications and transportation. Verimatrix offers easy-to-use software solutions, cloud services and silicon IP that provide unparalleled security and business intelligence. Proud to empower and protect its customers for more than two decades, Verimatrix serves IoT software developers, device makers, semiconductor manufacturers, service providers and content distributors. For more information, visit www.verimatrix.com.

Contact information

Media Contact
Kelly Foster
+1 619 224 1261
kfoster@verimatrix.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu